Hints and tips:
Related Special Reports
...Although AstraZeneca is in the race for a treatment, it is far behind the sector’s leaders Eli Lilly and Novo Nordisk....
...US drugmaker Eli Lilly is riding a wave of investor optimism and media hype about new treatments for two of the biggest public health problems: obesity and Alzheimer’s....
...Novo’s next generation drug CagriSema is biopharma’s most valuable R&D project, with a net present value of $30bn, according to Evaluate....
...He argued that the size of an R&D budget was not an automatic guarantee of success. “Two of the companies that had the lowest R&D spending a decade ago were Eli Lilly and Novo Nordisk....
...Eli Lilly inked a $250mn deal with Shenzhen-based Xtalpi in May. In July, Nvidia invested $50mn in US-based Recursion. Using AI does not guarantee success....
...Lilly Q4, Ford Q4, H&R Block Q2, Gartner Q4, Infineon Technologies Q1, Linde Q4, Mitsubishi Q3, Nintendo Q3, Omnicom Q4, Prudential Financial Q4, Snap Q4, Spotify Q4, Toyota Q3, UBS Q4, Virgin Money UK...
...China’s pharma researchers do a lot of R&D of their own, but do not seem to produce many blockbusters....
...Critics have also slammed industry leaders Eli Lilly and Biogen for charging excessive prices for treatments for common diseases such as diabetes and Alzheimer’s....
...Eli Lilly last year scrapped development of a drug targeting blood cancers. Bristol Myers Squibb has warned of similar moves....
...Ireland-based life science companies have tripled R&D spending, as they undertake higher value activities including manufacturing of complex biologic medicines....
...Bonnie Casson-Deweese anticipated last week’s clampdown by the US Supreme Court on affirmative action in college admissions....
...The UK’s share of global pharma R&D has dropped sharply since 2012, from 7.7 per cent to 4.2 per cent in 2020....
...Hopes are high for Eli Lilly’s new obesity drug Mounjaro. Like a similar drug from Novo Nordisk, it targets a brain area that regulates appetite....
...But a recent report for a European trade body found pharmaceutical R&D spending was growing faster in the US and China; Europe’s share of global R&D investment, clinical trials and manufacturing output are...
...Meanwhile, our share of the global pharmaceutical R&D market is declining....
...US drugmakers AbbVie and Eli Lilly in January became the first pharma companies to pull out of the voluntary scheme with the UK government in protest at the sharp rise in clawback payments....
...The industry is also worried that R&D productivity is falling....
...Novo Nordisk has followed Eli Lilly in slashing prices for some of its products by 75 per cent....
...“Pfizer is very good at selling but historically not renowned as having the R&D engine of a Merck or Lilly....
...It underpins Eli Lilly’s impressive record on innovation. It generated returns on R&D investment of nearly 14 per cent over the five years to 2021, according to Berenberg....
...But a friendly A&R man at his record company in London persuaded a local radio DJ to give it a spin. “It just blew up in England,” says Hornsby....
...The Eli Lilly drug usually used to treat rheumatoid arthritis tackles both the virus and the body’s inflammatory reaction....
...Eli Kaufman, executive director of the Los Angeles County Bicycle Coalition, is hoping to change this. “LA has the potential to become the next great bicycle region,” he says....
...Clayton, Dubilier & Rice has hired former Food and Drug Administration deputy commissioner for medical and scientific affairs Anand Shah as an operating adviser to CD&R funds....
...Vice-Chairman, Wan Hai Lines Cheng-Mount Cheng Chairman, Yang Ming Marine Transport Corp Matthew J Cox Chairman & Chief Executive, Matson Inc Thomas B Crowley Owner & Chief Executive, Crowley Maritime Eli...
International Edition